DE602004018338D1 - Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund - Google Patents

Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund

Info

Publication number
DE602004018338D1
DE602004018338D1 DE602004018338T DE602004018338T DE602004018338D1 DE 602004018338 D1 DE602004018338 D1 DE 602004018338D1 DE 602004018338 T DE602004018338 T DE 602004018338T DE 602004018338 T DE602004018338 T DE 602004018338T DE 602004018338 D1 DE602004018338 D1 DE 602004018338D1
Authority
DE
Germany
Prior art keywords
immune
prevention
treatment
inflammatory
related bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004018338T
Other languages
English (en)
Inventor
Thomas Wilckens
Ariane Volkmann Dr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onepharm Research and Development GmbH
Original Assignee
Onepharm Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onepharm Research and Development GmbH filed Critical Onepharm Research and Development GmbH
Publication of DE602004018338D1 publication Critical patent/DE602004018338D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE602004018338T 2003-09-22 2004-09-21 Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund Active DE602004018338D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
PCT/EP2004/010582 WO2005027882A1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Publications (1)

Publication Number Publication Date
DE602004018338D1 true DE602004018338D1 (de) 2009-01-22

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018338T Active DE602004018338D1 (de) 2003-09-22 2004-09-21 Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund

Country Status (15)

Country Link
US (2) US20100087413A1 (de)
EP (2) EP1663185B1 (de)
JP (1) JP2007533625A (de)
AT (1) ATE416761T1 (de)
AU (1) AU2004273610B2 (de)
CA (1) CA2539741A1 (de)
CY (1) CY1111246T1 (de)
DE (1) DE602004018338D1 (de)
DK (1) DK1663185T3 (de)
ES (1) ES2317029T3 (de)
NZ (1) NZ546062A (de)
PL (1) PL1663185T3 (de)
PT (1) PT1663185E (de)
SI (1) SI1663185T1 (de)
WO (1) WO2005027882A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026619A2 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using rnase h inhibitors
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
PL2322183T3 (pl) * 2006-06-01 2015-01-30 Santen Sas Wykorzystanie proleku do podawania doocznego, śródszklistkowego
AU2007271182B2 (en) 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
TW201016702A (en) 2008-09-25 2010-05-01 Shionogi & Co Novel pyrrolinone derivative and pharmaceutical composition comprising the same
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (de) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natürliche kombinationshormonersatzformulierungen und therapien
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (de) 2013-01-22 2017-07-12 Novartis AG Substituierte purinonverbindungen
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
MX2015016425A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
CA2931249A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
MA49761A (fr) * 2017-08-04 2020-06-10 Ardelyx Inc Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
SG11202108541RA (en) * 2019-02-07 2021-09-29 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
EP0496520A1 (de) * 1991-01-22 1992-07-29 Merck & Co. Inc. Knochenaktive Verbindungen
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0105772D0 (en) 2001-03-08 2001-04-25 Sterix Ltd Use
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AU2002353718B2 (en) 2001-11-22 2007-05-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003044000A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7205147B2 (en) 2002-09-23 2007-04-17 E.I. Du Pont De Nemours And Company Nucleic acids encoding ryanodine receptors
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2539741A1 (en) 2005-03-31
AU2004273610B2 (en) 2010-07-01
US20100087413A1 (en) 2010-04-08
ATE416761T1 (de) 2008-12-15
SI1663185T1 (sl) 2009-04-30
PT1663185E (pt) 2009-02-16
US20110275584A1 (en) 2011-11-10
EP2036548A1 (de) 2009-03-18
EP1663185B1 (de) 2008-12-10
PL1663185T3 (pl) 2009-06-30
NZ546062A (en) 2009-09-25
CY1111246T1 (el) 2015-06-11
WO2005027882A1 (en) 2005-03-31
AU2004273610A1 (en) 2005-03-31
JP2007533625A (ja) 2007-11-22
ES2317029T3 (es) 2009-04-16
DK1663185T3 (da) 2009-04-06
EP1663185A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
PT672658E (pt) Agentes antitromboticos
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE69716823T2 (de) Thrombin-Inhibitoren als anticoagulierende Mittel
DE60214730D1 (de) Platelet adp rezeptor inhibitoren
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE471315T1 (de) Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE10394347T5 (de) Eine synergistische Zusammensetzung zur Behandlung von Hyperlipidämie
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
ATE401321T1 (de) Beta-lactame zur behandlung von erkrankungen des zns
DE60216979D1 (de) Synergistische zusammensetzung aus trans-tetracos-15-ensäure und apocynin, und verwendung davon
SE9901273D0 (sv) Novel compounds
ATE340193T1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition